Method of preventing graft versus host disease
AssigneeMillennium Pharmaceuticals, Inc.
InventorsJessica A. SACHS, John E. FORD
Life of this patent
Estimating the term…
Abstract
A method for preventing GvHD in a human patient, comprising administering to a patient suffering from GvHD or at risk for GvHD, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has or is going to have an allogeneic stem cell transplantation, and wherein the dosing regimen prevents, improves or eliminates GvHD.
Claims61
A method of preventing graft versus host disease (GvHD), wherein the method comprises the step of:
- administering to a human patient undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a humanized antibody having binding specificity for human α4β7 integrin,
- wherein the humanized antibody is administered to the patient according to the following dosing regimen:
- a. an initial dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion the day before allo-HSCT;
- b. followed by a second subsequent dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion at about two weeks after the initial dose;
- c. followed by a third subsequent dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion at about six weeks after the initial dose;
- further wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
- Light chain:
- CDR1 SEQ ID NO:7
- CDR2 SEQ ID NO:8 and
- CDR3 SEQ ID NO:9;
- and
- Heavy chain:
- CDR1 SEQ ID NO:4
- CDR2 SEQ ID NO:5 and
- CDR3 SEQ ID NO:6.
A method of treating a patient suffering from cancer or a nonmalignant hematological, immunological disease or autoimmune disease, comprising the steps of:
- a. conditioning the immune system of the patient for hematopoietic stem cell transplant,
- b. administering a humanized antibody having binding specificity for human α4β7 integrin,
- c. waiting at least 12 hours,
- d. administering allogeneic hematopoietic stem cells,
- e. waiting thirteen days, then administering a second dose of humanized antibody having binding specificity for human α4β7 integrin, and
- f. waiting four weeks, then administering a third dose of humanized antibody having binding specificity for human α4β7 integrin.
A method reducing the occurrence of acute graft versus host disease (GvHD), wherein the method comprises the step of:
- administering to a human patient undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a humanized antibody having binding specificity for human α4β7 integrin,
- wherein the humanized antibody is administered to the patient according to the following dosing regimen:
- a. an initial dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion the day before allo-HSCT;
- b. followed by a second subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about two weeks after the initial dose;
- c. followed by a third subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about six weeks after the initial dose;
- wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
- Light chain:
- CDR1 SEQ ID NO:7
- CDR2 SEQ ID NO:8 and
- CDR3 SEQ ID NO:9;
- and
- Heavy chain:
- CDR1 SEQ ID NO:4
- CDR2 SEQ ID NO:5 and
- CDR3 SEQ ID NO:6,
- thereby reducing the occurrence of GvHD.
A method of suppressing an immune response in a cancer patient, wherein the method comprises the step of:
- administering to a human patient undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a humanized antibody having binding specificity for human α4β7 integrin,
- wherein the humanized antibody is administered to the patient according to the following dosing regimen:
- a. an initial dose of 75 mg, 300 mg, 450 mg or 600 mg of the humanized antibody as an intravenous infusion the day before allo-HSCT;
- b. followed by a second subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about two weeks after the initial dose;
- c. followed by a third subsequent dose of 300 mg of the humanized antibody as an intravenous infusion at about six weeks after the initial dose;
- further wherein the humanized antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
- Light chain:
- CDR1 SEQ ID NO:7
- CDR2 SEQ ID NO:8 and
- CDR3 SEQ ID NO:9;
- and
- Heavy chain:
- CDR1 SEQ ID NO:4
- CDR2 SEQ ID NO:5 and
- CDR3 SEQ ID NO:6.
A method of treating a transplant patient, wherein the transplant patient is a recipient of an infusion of allogeneic hematopoietic cells, comprising administering an anti-α4β7 antagonist.
Dependencies are inferred from the claim text.